Utility of the Interferon-Gamma Release Assay for Latent Tuberculosis Infection Screening among Indian Health-Care Workers

Sunita Girish, Aarti Kinikar1, Geeta Pardeshi2, Sangita Shelke3, Anita Basavaraj4, Ajay Chandanwale5, Dileep Kadam6, Samir Joshi7, Gauri Dhunat8, Nilima Lokhande9, Andrea Deluca9, Nikhil Gupte8, Amita Gupta8,9, Robert C Bollinger7,11, Vidya Mave8,10

Department of Biochemistry, 1Paediatrics, 2Community Medicine, 3Orthopaedics and 4ENT, Byramjee Jeejeebhoy Government Medical College–Sassoon General Hospital, 5Byramjee Jeejeebhoy Government Medical College–Johns Hopkins Clinical Trials Unit, 6Department of Medicine, Smt.Kashibai Navale Medical College and General Hospital, Pune, 7Department of Medicine, Government Medical College, Miraj, Maharashtra, 8Department of Community Medicine, Vardhaman Mahavir Medical College and Safdarjung Hospital, New Delhi, India, 9Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, 10Medicine and Public Health, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, 11Medicine, Public Health, and Nursing, Division of Infectious Diseases, Johns Hopkins University School of Medicine, MD, USA

Abstract

Background: The utility of interferon-gamma release assays (IGRAs) for latent tuberculosis infection (LTBI) screening among health-care workers (HCWs) in low- and middle-income countries (LMICs) remains unclear. Methods: This was a prospective cohort study among HCW trainees undergoing annual LTBI screening via tuberculin skin test (TST) and QuantiFERON® TB Gold Test-in-tube (QFT-GIT) in Pune, India. TST induration ≥ 10 mm and QFT-GIT ≥ 0.35 IU/ml were considered positive. Test concordance was evaluated at entry among the entire cohort and at 1 year among baseline TST-negative participants with follow-up testing. Overall test agreement was evaluated at both timepoints using the kappa statistic: fair (k < 0.40), good (0.41 ≥ k ≤0.60), or strong (k > 0.60). Results: Of 200 participants, prevalent LTBI was detected in 42 (21%) via TST and 45 (23%) via QFT-GIT; QFT-GIT was positive in 27/42 (64%) TST-positive and 18/158 (11%) TST-negative trainees. Overall test concordance was 84% (k = 0.52; 95% confidence interval [CI]: 0.38–0.66) and 80% (k = 0.44; 95% CI: 0.29–0.59) at baseline and 12 months, respectively. Conclusions: We observed good overall agreement between TST and QFT-GIT, and QFT-GIT detected additional LTBI cases among TST-negative trainees with possible early detection of LTBI conversion. Overall, our results support the use of IGRA for annual LTBI screening among HCWs in a high burden LMIC setting.

Keywords: Concordant and discordant test results, health-care workers, latent tuberculosis infection, Quanti FERON® TB Gold Test-in-tube (QFT-GIT), tuberculin skin test

Introduction

Tuberculosis (TB) poses a significant risk to health-care workers (HCWs) in low- and middle-income countries (LMICs).1-3 In India, the 2018 TB notification rate was at least 6-fold higher among HCWs than the general population.4 Critical World Health Organization (WHO)-recommended interventions include infection prevention and control measures as well as regular HCW latent tuberculosis infection (LTBI) screening along with preventive TB treatment.5 However, which screening test should be used, the tuberculin skin test (TST) or the interferon gamma release assay (IGRA) for LTBI, remains unclear.

The limitations of TST (e.g., Bacillus Calmette–Guerin [BCG] cross-reaction, persistent positivity, and arbitrary induration cutoffs6) and IGRA (e.g., unexplained conversions/reversions7) are well known. Notably, 2018 WHO guidelines

Access this article online

Quick Response Code:  
Website: www.ijcm.org.in  
DOI: 10.4103/ijcm.IJCM_761_20

Address for correspondence: Dr. Sunita Girish, Department of Biochemistry, Byramjee Jeejeebhoy Government Medical College–Sassoon General Hospital, Pune-411001, Maharashtra, India. E-mail: drsunitagirish@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Girish S, Kinikar A, Pardeshi G, Shelke S, Basavaraj A, Chandanwale A, et al. Utility of the interferon-gamma release assay for latent tuberculosis infection screening among Indian health-care workers. Indian J Community Med 2021;46:281-4.

Received: 04-09-20, Accepted: 31-03-21, Published: 29-05-21
deem the two tests to be equivalently imprecise and recommend either for LTBI screening among high-risk population groups, yet this strong recommendation is based on very low-quality evidence.[8] Currently, IGRA tests are more commonly used in high-income settings[9] due to the inter-rater variability in assessing TST induration.[10] There is, however, little evidence concerning the utility of IGRA and the concordance of TST and IGRA among HCWs with high TB exposure from LMIC health-care settings.

In the context of the world’s largest underlying TB burden, India reports high rates of LTBI and TB disease among HCWs.[11-14] Currently, LTBI screening remains limited to TST due to presumed inaccuracy.[15] We examined the concordance of TST and IGRA during annual LTBI screening among a prospective longitudinal cohort of HCW trainees established at a large public teaching hospital in Pune, India. Our results may have implications for the use of IGRA among HCWs in India and other high TB burden LMIC settings.

Methods

Between May 2016 and December 2017, a prospective cohort of HCW trainees (medical residents and nursing students) was established at Byramjee Jeejeebhoy Government Medical College (BJGMC) in Pune, India. The primary outcome was LTBI incidence. Study methods have been described in detail elsewhere.[16] Briefly, the cohort included medical residents and nursing students ages ≥18 years with no previous history of active TB. Following written informed consent, detailed demographic and clinical histories of the participants were recorded in clinical record form.[16] Participants underwent LTBI testing via TST and QuantiFERON® TB Gold Test-in-tube (QFT-GIT; Cellestis Ltd.) at study entry and 12 months; additional QFT-GIT testing was done at 1, 3, 6, and 9 months. Immediately following the 3 ml blood collection for QFT-GIT (performed and analyzed according to manufacturer instructions), TST (Span Diagnostics, India) was administered (5 units of purified protein derivative), and the reaction was read at 48–72 h. TST induration ≥10 mm and QFT-GIT ≥0.35 IU/ml were considered positive. The study was approved by the Ethics Committee and Institutional Review Board at BJGMC, India, and Johns Hopkins University, USA.

For this analysis, we examined TST and IGRA results at baseline among the overall cohort and at 12 months among a subcohort of baseline TST-negative HCWs. For each timepoint, test results were summarized as TST+/IGRA+, TST−/IGRA−, TST+/IGRA−, or TST−/IGRA+. We calculated the proportion of TST-positive cases detected by IGRA (TST+/IGRA+) and the proportion of TST-negative cases identified as LTBI by IGRA (i.e., additional LTBI cases identified by IGRA; TST−/IGRA+). To assess overall test concordance, we calculated the proportion of concordant results (TST+/IGRA+ plus TST−/IGRA−) at both timepoints and assessed agreement using the kappa statistic (k) with 95% confidence interval (CI); agreement was categorized as fair (k < 0.40), good (0.41 ≤ k ≤ 0.60), or strong (k > 0.60).[17] All analyses were performed using STATA version 13.1 (STATA 13.1, Copyright 1985-2015 StataCorp LP, StataCorp, Lakeway Drive, College Station, Texas, USA).

Results

Study population characteristics have been described elsewhere.[16] Briefly, the overall cohort (n = 200) was comprised of 90 (45%) nursing students and 110 (55%) medical residents, the median age was 25 (interquartile range, 19–27) years, and 89 (45%) reported exposure to a sputum smear-positive TB patient in the past 1 year.

Table 1 summarizes TST and IGRA results at study entry and 12 months. Baseline LTBI prevalence was 21% (n = 42) and 22% (n = 45) via TST and IGRA, respectively. QFT-GIT detected 27 (64%) of the 42 TST-positive HCWs (i.e., TST+/IGRA+) and identified 18 (11%) additional LTBI cases among the 158 TST-negative HCWs. Of these TST−/IGRA + HCWs, 53% (n = 10/18) reported contact with a sputum smear-positive TB patient, and interferon-gamma levels ranged between 0.41 IU/ml and 6.96 IU/ml; 50% (n = 9/18) had QFT-GIT >0.7 IU/ml.

The analysis at 12 months included 142 HCWs who were TST negative at entry and had TST and IGRA results at 1 year (Table 1). Annual LTBI incidence (conversion at 1 year) was 28% (n = 40) via TST; of these, 11 (28%) HCWs were identified by IGRA at study entry (i.e., baseline TST−/IGRA+). QFT-GIT detected 17 (43%) of the 40 TST-positive HCWs (TST+/IGRA+) and identified 5 (5%) additional LTBI cases among the 102 HCWs who remained TST negative. Of these TST−/IGRA + HCWs, 40% (2/5) reported contact with a sputum smear-positive TB patient and, interferon-gamma levels ranged between 0.35 IU/ml and 2.18 IU/ml; one had QFT-GIT > 0.70 IU/ml.

Overall test concordance was observed in 167/200 (84%, k = 0.52; 95% CI: 0.38–0.66) at baseline and 114/142 (80%, k = 0.44; 95% CI: 0.29–0.59) at 1 year, corresponding to good agreement.

Discussion

This prospective cohort study suggests good overall agreement between TST and IGRA during annual LTBI screening among HCW trainees in India.[18-20] In addition, QFT-GIT identified LTBI among TST-negative HCWs with possible early LTBI detection among 28% of HCW trainees before TST conversion was observed in annual follow-up. Overall, our study provides country-specific data supporting the use of IGRA among HCWs.

In our cohort, LTBI prevalence was nearly equivalent whether determined by TST or IGRA. A recent systematic review of studies conducted among HCWs in LMICs between 2005 and 2017 also reported similar pooled LTBI prevalence in high TB burden countries via TST (55%; n = 5 studies) and...
IGRA (56%; \( n = 3 \) studies).\(^7\) Fewer studies have assessed overall agreement between IGRA and TST among HCWs in similar settings. Compared to the good baseline test agreement observed in our relatively small cohort (84%; \( k = 0.52 \)), an analysis of prevalent LTBI among HCWs in Brazil (\( n = 664 \)) found low test agreement (69%; \( k = 0.31 \)),\(^{121} \) yet agreement was found to be high (81.4%; \( k = 0.61 \)) in a study among 726 HCWs in rural India.\(^{131} \) Notably, our longitudinal study design allowed us to follow LTBI status over time, revealing that 61% of the additional LTBI cases identified by QFT-GIT at entry (i.e., TST\(\sim\)IGRA+) had TST conversion at 1-year follow-up. Although QFT-GIT levels have not yet been optimized for the Indian population,\(^{22} \) our findings suggest early LTBI detection among 28% of HCWs with annual TST conversion; applying the certainty cutoff, QFT-GIT >0.70 IU/ml would still identify 10 additional HCWs as LTBI positive.

Our study provides new data supporting the most recent WHO LTBI guidelines. In the context of good test concordance, the decision to limit LTBI screening to TST in India should be driven by factors other than individual test precision.\(^{18} \) Particularly in health-care settings with existing laboratory infrastructure and expertise, IGRA may be better positioned than TST to overcome barriers to regular LTBI screening among HCWs in LMICs. Specifically, low perceived TB risk, complacency, and TB stigma among clinic staff/hospital administrators may be mitigated by the one-visit convenience of a single blood draw.\(^{21,24} \) IGRA also eliminates the impact of BCG cross-reaction, boosting with serial screening, and global shortages make it an attractive option for health-care institutions in LMICs.\(^{1,25} \)

**Conclusion**

Finally, the potential for early detection of LTBI status conversion suggested by our study might allow for earlier initiation of preventive TB treatment among some HCWs.

**Acknowledgments**

We thank the study participants for their immense contribution. We also thank Katir McIntyre for her help in editing the manuscript.

---

**Table 1: Summary of concordant and discordant results of the tuberculin skin test and interferon-gamma release assay during annual latent tuberculosis infection screening among health-care worker trainees in Pune, India**

| Interferon-gamma release assay* | Tuberculin skin test | Total |
|--------------------------------|----------------------|-------|
|                                | \( \geq 10 \text{ mm (positive)} \) | \( <10 \text{ mm (negative)} \) |       |
| Baseline (IU/ml)               |                      |       |
| \( \geq 0.35 \) (positive)     | 27                   | 18    | 45   |
| \( <0.35 \) (negative)        | 15                   | 140   | 155  |
| Total                          | 42                   | 158   | 200  |
| 12 months (IU/ml)              |                      |       |
| \( \geq 0.35 \) (positive)     | 17                   | 5     | 22   |
| \( <0.35 \) (negative)        | 23                   | 97    | 120  |
| Total                          | 40                   | 102   | 142  |

*Quantiferon® TB Gold Test-in-tube (Cellestis Ltd.)*

---

**Financial support and sponsorship**

This study was supported by the National Institute of Health (NIH) Supplement for BWI Clinical Trials Unit for NIAID Networks (UM1) (P.I. Flexner/Gupta, UM01AI069465) and the BJGMTC JHU HIV TB Program funded by the Fogarty International Center, NIH (grant # D43TW009574). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors also acknowledge support from Persistent Systems in kind.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. World Health Organization. Global Tuberculosis Report 2016; 2016 Available from: http://www.who.int/tb/publications/global_report/en/. [Last accessed on 2016 Oct 20].
2. Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low- and middle-income countries: A systematic review. PLoS Med 2006;3:e494.
3. Baussano I, Nunn P, Williams B, Pivetta E, Bugiani M, Scano F. Tuberculosis among health care workers. Emerg Infect Dis 2011;17:488-94.
4. World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization; 2019. Available from: https://apps.who.int/iris/bitstream/handle/10665/329568/9789241565714-eng.pdf?ua=1. [Last accessed on 2019 Jan 21].
5. World Health Organization. WHO Policy on TB Infection Control in Health-Care Facilities, Congregate Settings and Households. Geneva, Switzerland: World Health Organization; 2009.
6. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161:S221-47.
7. Apriani L, McAllister S, Sharples K, Alijahbana B, Ruslami R, Hill PC, et al. Latent tuberculosis infection in healthcare workers in low- and middle-income countries: an updated systematic review. Eur Respir J. 2019;53:1801789. doi: 10.1183/13993003.01789-2018. PMID: 30792341.
8. World Health Organization. Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management. Geneva: World Health Organization; 2018. Available from: https://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/. [Last accessed...
9. Zwerling A, van den Hof S, Scholten J, Cobelens F, Menzies D, Pai M. Interferon-gamma release assays for tuberculosis screening of healthcare workers: A systematic review. Thorax 2012;67:62-70.

10. Centers for Disease Control and Prevention. Tuberculin Skin Testing. Available from: https://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm. [Last accessed on 2017 Jan 23].

11. Basavaraj A, Chandanwale A, Patil A, Kadam D, Joshi S, Gupte N, et al. Tuberculosis Risk among Medical Trainees, Pune, India. Emerg Infect Dis 2016;22:541-3.

12. Christopher DJ, Daley P, Armstrong L, James P, Gupta R, Premkumar B, et al. Tuberculosis infection among young nursing trainees in South India. PLoS One 2010;5:e10408.

13. Pai M, Gokhale K, Joshi R, Dogra S, Kalantri S, Mendiratta DK, et al. Mycobacterium tuberculosis infection in health care workers in rural India: Comparison of a whole-blood interferon gamma assay with tuberculin skin testing. JAMA 2005;293:2746-55.

14. Mathew A, David T, Thomas K, Kuruvilla PJ, Balaji V, Jesudason MV, et al. Risk factors for tuberculosis among health care workers in South India: A nested case-control study. J Clin Epidemiol 2013;66:67-74.

15. Down to Earth News. Government Bans Blood Test for TB. Available from: https://www.downtoearth.org.in/news/government-bans-blood-test-for-tb-38473. [Last accessed on 2019 Jan 21].

16. Kinikar A, Chandanwale A, Kadam D, Joshi S, Basavaraj A, Pardeshi G, et al. High risk for latent tuberculosis infection among medical residents and nursing students in India. PLoS One 2019;14:e0219131.

17. El-Helaly M, Khan W, El-Saed A, Balkhy HH. Pre-employment screening of latent tuberculosis infection among healthcare workers using tuberculin skin test and Quantiferon-TB Gold test at a tertiary care hospital in Saudi Arabia. J Infect Public Health 2014;7:481-8.

18. Overton K, Varma R, Post JI. Comparison of interferon-γ release assays and the tuberculin skin test for diagnosis of tuberculosis in human immunodeficiency virus: A systematic review. Tuberc Respir Dis (Seoul) 2018;81:59-72.

19. Denkinger CM, Dheda K, Pai M. Guidelines on interferon-γ release assays for tuberculosis infection: Concordance, discordance or confusion? Clin Microbiol Infect 2011;17:806-14.

20. Diel R, Nienhaus A. Current issues arising from tuberculosis screening with interferon-gamma-release assays (IGRAs). Pneumologie 2015;69:271-5.

21. de Souza FM, do Prado TN, Pinheiro Jdos S, Peres RL, Lacerda TC, Loureiro RB, et al. Comparison of interferon-γ release assay to two cut-off points of tuberculin skin test to detect latent Mycobacterium tuberculosis infection in primary health care workers. PLoS One 2014;9:e102773.

22. Nemes E, Rozot V, Geldenhuyys H, Bilek N, Mahwe S, Abrahams D, et al. Optimization and interpretation of serial QuantiFERON testing to measure acquisition of Mycobacterium tuberculosis infection. Am J Respir Crit Care Med 2017;196:638-48.

23. van Cutsem G, Isaakidis P, Farley J, Nardell E, Volechenkov G, Cox H. Infection control for drug-resistant tuberculosis: Early diagnosis and treatment is the key. Clin Infect Dis 2016;62 Suppl 3: S238-43.

24. Pardeshi SG, Kadam D, Chandanwale A, Deluca A, Khobragade P, Parande M, et al. TB risk perceptions among medical residents at a tertiary care center in India. Tuberculosis 2017;2017:7514817.

25. Mathad JS, Bhosale R, Balasubramanian U, Kanade S, Mave V, Suryavanshi N, et al. Quantitative IFN-γ and IL-2 response associated with latent tuberculosis test discordance in HIV-infected pregnant women. Am J Respir Crit Care Med 2016;193:1421-8.